Newsroom | 5337 results

MIAMI & OTTAWA, Ontario--(BUSINESS WIRE)--OpenEvidence and the Medical Identification Number for Canada Corporation (MINC#NIMC) today announced a partnership to streamline physician verification for Canada and support continued free access for verified Canadian clinicians. Medical knowledge keeps accelerating, and clinicians do not have time to chase down answers across dozens of tabs and paywalls. This partnership reduces friction at the moment of sign-up by allowing Canadian physicians to ver...

RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Glucotrack announces $11.5M convertible note financing, including new capital and note rollover, to support strategic growth....

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026. Mr. Boehnlein is a highly accomplished healthcare executive and finance leader with more than 20 years of experience in the medical technology industry. Most recently, he served as Vice President and Chief Financial Officer of Stryker Corporation, one of the world’s leading medical technology...

PARIGI--(BUSINESS WIRE)--BioLife ha annunciato oggi che lo United States Patent and Trademark Office ha concesso il brevetto statunitense 12,667,605 B2 alla sua innovativa tecnologia di somministrazione orale effervescente dei peptidi, sviluppata per supportare le terapie peptidiche attuali e future per l’obesità, il diabete e le malattie metaboliche. L'annuncio coincide con un momento di rapida crescita della domanda di farmaci a base di GLP-1. Nel 2025, le terapie a base di GLP-1 hanno genera...

PARÍS--(BUSINESS WIRE)--BioLife ha anunciado hoy que la United States Patent and Trademark Office ha concedido la patente estadounidense n.º 12.667.605 B2 por su novedosa tecnología de administración oral efervescente de péptidos, diseñada para complementar los tratamientos actuales y futuros con péptidos para la obesidad, la diabetes y las enfermedades metabólicas. El anuncio se produce en un momento en el que la demanda de medicamentos con GLP-1 sigue creciendo a un ritmo acelerado. Las terap...

PARIJS--(BUSINESS WIRE)--BioLife maakte vandaag bekend dat de United States Patent & Trademark Office het Amerikaanse octrooi 12,667,605 B2 heeft toegekend voor zijn nieuwe technologie voor bruisende orale toediening van peptiden, ontworpen om huidige en toekomstige peptidentherapieën voor obesitas, diabetes en stofwisselingsstoornissen te ondersteunen. Deze aankondiging wordt gedaan op een moment dat de vraag naar GLP-1-geneesmiddelen blijft toenemen. GLP-1-therapieën genereerden om en bij...

PARIS--(BUSINESS WIRE)--BioLife a annoncé aujourd’hui que l’Office américain des brevets et des marques avait délivré le brevet américain n° 12 667 605 B2 portant sur sa nouvelle technologie d’administration orale de peptides sous forme effervescente, conçue pour les traitements peptidiques actuels et futurs contre l’obésité, le diabète et les maladies métaboliques. Cette annonce intervient alors que la demande de médicaments à base de GLP-1 continue de croître rapidement. Les traitements à bas...

PARIS--(BUSINESS WIRE)--BioLife gab heute bekannt, dass das US-Patent- und Markenamt das US-Patent 12.667.605 B2 für seine neuartige Technologie zur oralen Peptidverabreichung mit Brausetabletten erteilt hat. Sie wurde für heutige und künftige Peptidtherapien gegen Adipositas, Diabetes und Stoffwechselerkrankungen entwickelt. Die Bekanntgabe erfolgt vor dem Hintergrund einer rasant wachsenden Nachfrage nach GLP-1-Medikamenten. GLP-1-Therapien erzielten 2025 weltweit einen Umsatz von rund 132 Mi...

PARIS--(BUSINESS WIRE)--Oral semaglutide achieves measurable systemic exposure in preclinical studies; patent claims extend to multiple GLP-1 agonists....

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Ashvattha Therapeutics ("Ashvattha"), a clinical-stage company developing an at-home subcutaneous (subQ) monthly treatment, announced presentations at HC Wainwright Conference, Ophthalmology Futures Retina Forum, and EURETINA, highlighting clinical trial results of migaldendranib (MGB) for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). Globally, approximately half (50%) of DME and nAMD patients discon...